Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK's malaria vaccine to go to regulators in 2014

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline's pioneering malaria vaccine looks like it could arrive within two years. The company says it will file for approval of the RTS,S vaccine with the European Medicines Agency next year, based on the latest data from its large-scale Phase III trial. It added that the World Health Organization has indicated that a policy recommendation for the RTS,S malaria vaccine candidate is possible as early as 2015 if it is granted a positive scientific opinion by EMA, paving the way for decisions by African nations regarding large-scale implementation of the vaccine through their national immunization programs.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC023033

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel